Development and Validation of an LC–MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma

Eva Greibe, Jakob N. Henriksen, Niels Fristrup, Elke Hoffmann-Lücke

Open source

DOI
10.3390/ph19081180
Published
2026-07-28
Container
Pharmaceuticals
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ph19081180,
  title = {Development and Validation of an LC–MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma},
  author = {Eva Greibe and Jakob N. Henriksen and Niels Fristrup and Elke Hoffmann-Lücke},
  year = {2026},
  journal = {Pharmaceuticals},
  doi = {10.3390/ph19081180},
  url = {https://doi.org/10.3390/ph19081180}
}

RIS

TY  - JOUR
TI  - Development and Validation of an LC–MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma
AU  - Eva Greibe
AU  - Jakob N. Henriksen
AU  - Niels Fristrup
AU  - Elke Hoffmann-Lücke
PY  - 2026
JO  - Pharmaceuticals
DO  - 10.3390/ph19081180
UR  - https://doi.org/10.3390/ph19081180
ER  - 

APA

Greibe, E., Henriksen, J. N., Fristrup, N., & Hoffmann-Lücke, E. (2026). Development and Validation of an LC–MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma. Pharmaceuticals. https://doi.org/10.3390/ph19081180

Source records